Added to YB: 2026-09-15
Pitch date: 2026-09-12
ANIX [neutral]
Anixa Biosciences, Inc.
+0.36%
current return
Author Info
No bio for this author
Company Info
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Market Cap
$96.3M
Pitch Price
$2.79
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.45
P/E
-8.94
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference Coverage day 4 session 3 - Anixa Biosciences, Inc.
ANIX (quick overview): Anixa is an early-stage oncology option with two differentiated but unproven programs: an FSHR-targeted, intraperitoneal CAR-T for recurrent ovarian cancer and an alpha-lactalbumin breast-cancer vaccine. Higher-dose CAR-T data with formal objective responses and safety are the highest-value near-term event; management reported ~75% protocol-defined immune responses for the vaccine, which now needs Phase 2 clinical efficacy. Without clearer efficacy, scalable manufacturing and a defensible registration path, the M&A case is not yet strong.
Read full article (2 min)